Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06628375

A Multimodal Study of the Relationship Between Exposure to Endocrine Disruptors and Occurrence of Hypospadias - HYPOLLUT

This study aims to demonstrate the impact of Endocrine-Disrupting Chemicals (EDCs) on the risk of hypospadias incidence. It is a multicenter comparative case-control study, involving two groups. The first group consists of biological mothers who have given birth to children with hypospadias (Case Group), while the second group consists of biological mothers who have given birth to children without any malformations (Control Group). Through an integrative approach that combines a direct toxicological study of numerous pollutants present during pregnancy, and a comprehensive exposome assessment using validated tools, this study can significantly enhance our understanding and prevention of this malformation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

1 month and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CRMR DEVGEN CHU Lapeyronnie

Montpellier, Hérault, 34090, France

Location status: Recruiting

About this study

Background. Hypospadias is a birth defect of the external genital organs in boys and it ranks the second most common genital malformation in male newborns, following cryptorchidism. Its prevalence is increasing in certain global regions, with an estimated rate of 3.8 cases per 1000 male births. To date, the exact cause of hypospadias remains unknown, however genetic, hormonal, and environmental factors are likely involved. Medical and surgical treatment may be necessary. Furthermore, hypospadias is correlated with fertility issues and is also linked to testicular cancer.

Aim. After ruling out hypospadias with a genetic cause, the aim of this study is to evaluate any significant differences to environmental endocrine disrupting-chemicals (EDCs) exposure between biological mothers of children with hypospadias and those with children without malformation. It aims to demonstrate that this exposure (professional, occupational, environmental) leads to hormonal changes during the neonatal mini-puberty period.

Methods. This research will be conducted as a multicenter case-control study: mother and son with isolated anterior or middle hypospadias (Case Group) and mother and son without hypospadias (Control Group). The clinical investigator plans to enroll 200 patients.

A single visit will be performed. This consultation is part of the usual follow-up for children in the Case Group, while it is specific to the project for children in the Control Group.

During this visit, the investigator:

  • will establish the diagnosis of hypospadias (for cases) or absence of genital anomaly (for controls)
  • will lead an interview using a questionnaire and a job-exposure matrix to assess EDCs during pregnancy
  • will take a hair sample from the mother to measure the substances accumulated during pregnancy
  • and finally, will take a blood sample from the child for hormonal evaluation of mini-puberty, and another blood sample from child in the Case Group for analysis and the participation in a DNA collection

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Non-specific Inclusion Criteria :

  • Parents of legal age having signed a free and informed consent for the participation of their child
  • Biological mother of a boy aged between 1 and 6 months
  • Biological mother with a minimum hair length of 18 cm
  • Biological mother who has signed a free and informed consent for her participation
  • Biological mother and child affiliated with or beneficiaries of a national health insurance plan
  • Biological mother who is fluent in written and spoken French

Specific Inclusion Criteria for Case Group:

  • The child has an isolated anterior or middle hypospadias, without any other complex variations of genital development (borderline penile size, unilateral or bilateral cryptorchidism, retractile testes), without malformation syndrome and without identified genetic etiology

Specific Inclusion Criteria for Control Group:

  • The child must not present any complex variations in genital development (hypospadias, borderline penis size, unilateral or bilateral cryptorchidism, retractile testes)

Exclusion criteria

  • Child with another congenital anomaly or malformative syndrome
  • Child with an endocrine pathology
  • Biological mother or child under legal protection, guardianship, or curatorship
  • Biological mother or child in the exclusion period of a previous study
  • Biological mother or child included in another clinical study involving a drug

Specific Exclusion Criteria for Case Group:

Biological mother/child pairs if a genetic variant explaining hypospadias is found during genetic analysis.

Treatment and study plan

Consultation visit (Visit 1)

Other

During visit 1, a pediatric urologist or pediatric endocrinologist will perform a clinical examination to confirm the diagnosis of hypospadias, as a part of routine care. The clinical study investigator will ask to fill out a validated European questionnaire for the exposome and use an occupation/exposure matrix to identify specific atmospheric exposure.

A hair sample from the biological mother will be taken for toxicological evaluation of substances accumulated during pregnancy.

From the child, a blood sample will be taken for hormonal evaluation of minipuberty and then, another sample in a 5 ml EDTA tube will be taken for DNA collection.

Primary outcomes

  1. Evaluation of toxic exposure via hair sample analysis

    Time frame: Day 1 (Visit 1)

    An assessment of toxic substance concentrations in maternal hair will evaluate exposure to a wide range of pollutants. The collected hair samples will provide data representing the period from three months before conception to the date of study enrollment.

    The study will analyze 150 chemical substances and measure their concentrations to assess mothers' exposure to these pollutants during pregnancy.

Secondary outcomes

  1. Exposome through validated European questionnaires (QLK4-1999-01422)

    Time frame: Day 1 (Visit 1)

    Evaluation of parents' environmental exposure (exposome) will be conducted using a simplified version of a validated European questionnaire. This approach aims to elucidate potential differences in exposure between case and control groups.

  2. Exposome professionnel

    Time frame: Day 1 (Visit 1)

    Assessment by the job-exposure matrix EDC (Environment disrupting chemicals)

  3. Pollutant dispersion model

    Time frame: Day 1 (Visit 1)

    Examination of atmospheric pollutant concentration measurements and their potential impact on maternal exposure during gestation. This study conducts a comparative analysis between two groups: mothers of affected children (case group) and mothers of unaffected children (control group).

  4. Hormonal analysis by immunoassay principle

    Time frame: Day 1 (Visit 1)

    Measurement of plasma hormone levels of mini-puberty to investigate a correlation between toxicological dosage and endocrine disruption. FSH, LH, AMH and free Testosterone will be measured by Electrochemiluminescence and Inhibin B by ELISA assay. This assessment of a mini-puberty alteration will be carried out by comparing age-based norms and the values of the control group

Study contacts

Contact information is provided by the study sponsor or research team.

Nicolas KALFA, Prof

CONTACT

[email protected]

0467338784

Sponsors and collaborators

Lead sponsor

University Hospital, Montpellier

Other

Registry information

Official study title

Exposure to Endocrine Disruptors and Occurrence of Hypospadias: Toxicological, Environmental and Hormonal Imbalance Study

Acronym: HYPOLLUT

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 8, 2024
Registry last updated
Nov 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.